Do activities of cytochrome P450 (CYP)3A,CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

Morgan E.T. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 2009; 85: 434–438.

Morgan E.T. , Goralski K.B. , Piquette-Miller M. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008; 36: 205–216.

Aitken A.E. , Morgan E.T. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 2007; 35: 1687–1693.

Morgan E.T. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 2001; 29: 207–212.

Chang K.C. , Lauer B.A. , Bell T.D. , Chai H. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978; 311: 1132–1133.

Carcillo J.A. , Doughty L. , Kofos D. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003; 29: 980–984.

Frye R.F. , Schneider V.M. , Frye C.S. , Feldman A.M. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 2002; 8: 315–319.

Slaviero K.A. , Clarke S.J. , Rivory L. P. . Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003; 4: 224–232.

O'Neil W.M. , Gilfix B.M. , DiGirolamo A. , Tsoukas C.M. , Wainer I.W. N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow? Clin Pharmacol Ther 1997; 62: 261–271.

O'Neil W.M. , Gilfix B.M. , Markoglou N. , Di Girolamo A. , Tsoukas C.M. , Wainer I.W. Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. Eur J Clin Pharmacol 2000; 56: 231–240.

O'Neil W.M. , Drobitch R.K. , MacArthur R.D. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics 2000; 10: 171–182.

O'Neil W.M. , Pezzullo J.C. , Di Girolamo A. , Tsoukas C.M. , Wainer I.W. Glucuronidation and sulphation of paracetamol in HIV-positive patients and patients with AIDS. Br J Clin Pharmacol 1999; 48: 811–818.

Wyen C. , Fuhr U. , Frank D. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 2008; 84: 75–82.

Tomalik-Scharte D. , Jetter A. , Kinzig-Schippers M. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 2005; 33: 1859–1866.

Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41: 67–76.

Chen M. , Ma L. , Drusano G.L. , Bertino J.S. Jr. , Nafziger A.N. Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther 2006; 80: 531–538.

He P. , Court M.H. , Greenblatt D.J. , Von Moltke L.L. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 2005; 77: 373–387.

Floyd M.D. , Gervasini G. , Masica A.L. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13: 595–606.

Bebia Z. , Buch S.C. , Wilson J.W. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004; 76: 618–627.

Aklillu E. , Herrlin K. , Gustafsson L.L. , Bertilsson L. , Ingelman-Sundberg M. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 2002; 12: 375–383.

Meibohm B. , Beierle I. , Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002; 41: 329–342.

Larsen U.L. , Hyldahl Olesen L. , Guldborg Nyvold C. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest 2007; 67: 123–134.

Becker Y. The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers – a review and hypothesis. Virus Genes 2004; 28: 5–18.

Welage L.S. , Carver P.L. , Revankar S. , Pierson C. , Kauffman C.A. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21: 1431–1438.

Guadalupe M. , Reay E. , Sankaran S. Severe CD4⁺ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77: 11708–11717.

Veazey R.S. , DeMaria M. , Chalifoux L.V. Gastrointestinal tract as a major site of CD4⁺ T cell depletion and viral replication in SIV infection. Science 1998; 280: 427–431.

Fuhr U. , Jetter A. , Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the ‘cocktail’ approach. Clin Pharmacol Ther 2007; 81: 270–283.

Kurnik D. , Wood A.J. , Wilkinson G.R. The erythromycin breath test refects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther 2006; 80: 228–234.

Lee J.I. , Chaves-Gnecco D. , Amico J.A. , Kroboth P.D. , Wilson J.W. , Frye R. F. . Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002; 72: 718–728.

Gorski J.C. , Jones D.R. , Haehner-Daniels B.D. , Hamman M.A. , O'Mara E.M. Jr. , Hall S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64: 133–143.

Tomalik-Scharte D. , Doroshyenko O. , Kirchheiner J. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. Eur J Clin Pharmacol 2008; 64: 1033–1035.

Borges S. , Li L. , Hamman M.A. , Jones D.R. , Hall S.D. , Gorski J.C. Dextromethorphan to dextrorphan urinary metabolic ratio does not refect dextromethorphan oral clearance. Drug Metab Dispos 2005; 33: 1052–1055.

Frank D. , Jaehde U. , Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007; 63: 321–333.

Hu O.Y. , Tang H.S. , Lane H.Y. , Chang W.H. , Hu T.M. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther 1998; 285: 955–960.

Yeh G.C. , Tao P.L. , Ho H.O. , Lee Y.J. , Chen J.Y. , Sheu M.T. Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. J Biomed Sci 2003; 10: 552–564.

Greiner B. , Eichelbaum M. , Fritz P. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147–153.

Hoffmeyer S. , Burk O. , von Richter O. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473–3478.

Ding R. , Tayrouz Y. , Riedel K.D. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004; 76: 73–84.

Jones A.E. , Brown K.C. , Werner R.E. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 2010; 66: 475–485.

Hariparsad N. , Nallani S.C. , Sane R.S. , Buckley D.J. , Buckley A.R. , Desai P.B. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44: 1273–1281.

Mouly S. , Lown K.S. , Kornhauser D. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72: 1–9.

Edwards P. , Wodak A. , Cooper D.A. , Thompson I.L. , Penny R. The gastrointestinal manifestations of AIDS. Aust N Z J Med 1990; 20: 141–148.

Dickinson L. , Khoo S. , Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 2008; 3: 296–305.

Le Tiec C. , Barrail A. , Goujard C. , Taburet A.M. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005; 44: 1035–1050.